Teligent Income After Taxes 2010-2021 | TLGT

Teligent income after taxes from 2010 to 2021. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Teligent Annual Income After Taxes
(Millions of US $)
2020 $-122
2019 $-25
2018 $-36
2017 $-15
2016 $-12
2015 $7
2014 $5
2013 $-0
2012 $-4
2011 $-3
2010 $-3
2009 $-5
Teligent Quarterly Income After Taxes
(Millions of US $)
2021-06-30 $-13
2021-03-31 $2
2020-12-31 $-80
2020-09-30 $-1
2020-06-30 $-14
2020-03-31 $-27
2019-12-31 $-5
2019-09-30 $-7
2019-06-30 $-4
2019-03-31 $-9
2018-12-31 $-14
2018-09-30 $-4
2018-06-30 $-13
2018-03-31 $-5
2017-12-31 $-6
2017-09-30 $-9
2017-06-30 $-1
2017-03-31 $1
2016-12-31 $-5
2016-09-30 $-3
2016-06-30 $-3
2016-03-31 $-1
2015-12-31 $-6
2015-09-30 $-3
2015-06-30 $9
2015-03-31 $7
2014-12-31 $6
2014-09-30 $-0
2014-06-30 $-0
2014-03-31 $0
2013-12-31 $1
2013-09-30 $-0
2013-06-30 $-0
2013-03-31 $-0
2012-12-31 $-1
2012-09-30 $-1
2012-06-30 $-1
2012-03-31 $-1
2011-12-31 $-1
2011-09-30 $-0
2011-06-30 $-1
2011-03-31 $-1
2010-12-31 $-1
2010-09-30 $-1
2010-06-30 $-1
2010-03-31 $-1
2009-12-31 $-1
2009-09-30 $-1
2009-06-30 $-2
2009-03-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.000B $0.000B
Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Amphastar Pharmaceuticals (AMPH) United States $2.335B 14.04
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00